

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/44 // (A61K 31/44, 31:165)</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/37886</b> <b>(43) International Publication Date:</b> 3 September 1998 (03.09.98)
<b>(21) International Application Number:</b> PCT/IT98/00040 <b>(22) International Filing Date:</b> 26 February 1998 (26.02.98) <b>(30) Priority Data:</b> CE97A000001 28 February 1997 (28.02.97) IT <b>(71)(72) Applicant and Inventor:</b> ANTROPOLI, Carmine [IT/IT]; Via IV Novembre, 11, I-81020 Sant'Angelo in Formis (IT). <b>(74) Agent:</b> SARPI, Maurizio; Studio Ferrario, Via Collina, 36, I-00187 Roma (IT).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TOPICAL NIFEDIPINE PREPARATIONS FOR THE CONSERVATIVE TREATMENT OF FUNCTIONAL PATHOLOGIES OF THE ANAL CANAL  <b>(57) Abstract</b>  Pathologies of the anal canal, acute and chronic fissures, rhagades, spasm, haemorrhoids and tenesmus, as well as ischaemic cholangitis, bladder tenesmus and spasm are treated with topical preparations (e.g. suppositories) containing nifedipine (a known calcium antagonist), alone or in combination with antiinflammatory agents, mesclapine or other drug effective in the treatment of ulcerous recto-cholangitis or aspecific proctitis or with local anaesthetics such lidocaine or carbocaine.		

Reference No.: 37

Appln. No.: 10/669,099

Inventor(s): Gorfine, Stephen R.

Atty Docket No.: 010692-004532US

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Topical Nifedipine preparations for the conservative treatment of functional pathologies of the anal canal.

The present invention relates to the new use of Nifedipine, a well known active principle commonly used against heart and circulatory disorders. The new use is geared towards treatment of functional  
5 pathologies of the anal canal.

It is known from the literature that Nifedipine, that is a dimethyl ester of 1,4 dihydro-2,6 dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylic acid, is effective in the treatment of cardiovascular  
10 diseases and for that purpose oral administration is recommended.

Pathologies of the anal canal, acute and chronic fissure, haemorrhoids and tenesmus, are extremely common. About 30-40% of the population  
15 suffer from proctologic pathologies at least once in their lives. The disorders that derive from them are generally more annoying than dangerous. Therapy can be either conservative or surgical.

Proctologic diseases are eventually  
20 eradicated by a careful employment of surgical techniques, which have undergone a remarkable development in recent times but do indeed represent a defeat for pharmacological therapies.

Non invasive therapies are known but they  
25 have so far resorted to anti-inflammatory drugs as disclosed by W.Klug and H.G.Knoch in Colo-Proctology

(1993) 1, pp 22-28, and by McDonald et al. in the British Journal of Surgery (1983), 70, pp.25-26 and to other preparations from which Nifedipine was excluded.


Aim of the present invention is to propose  
5 the use of Nifedipine in medicaments for the treatment of proctologic pathologies like anal fissure, anal tenesmus and haemorrhoids, and to outline the main features of a therapy based on the above compound.

Such an aim has been accomplished thanks to  
10 the use of Nifedipine by local external application in therapies against pathologies comprising anal rhagades, rectal tenesmus, anal spasm, haemorrhoids, in suppository form for the treatment against ischemic cholangitis, bladder tenesmus and as a gel, cream or  
15 ointment by local application or in preparation colonoscopy and cystoscopy.

The present invention also comprises the use of Nifedipine in association with pharmaceuticals such as local anaesthetics like lidocaine, carbocaine, non-  
20 steroidal or caustic antiinflammatories, mesclapine, and with any pharmaceutical against ulcerous recto-cholangitis and aspecific proctites.

Nifedipine is a dihydropyridine whose structure is shown in Figure 1 below:

25



Part of its strong activity towards biological systems can be accounted for by the presence of the heterocyclic Nitrogen atom and the nitrated benzene ring which has enhanced electrophilic properties. Moreover, the double carboxy functionality confers a remarkable polarity to the handles and shifts the pyridine ring electrons in such a way as to drastically augment its reactivity in terms of a decrease in its inherent nucleophilicity given by the Nitrogen lone pair of electrons that becomes less available as such.

Its interaction with biological systems is by and large determined by the fact that as a dihydropyridine, it is a calcium antagonist at present administered only orally for the treatment of cardiovascular disorders on the basis of the fact that it induces relaxation of the vascular walls.

The same mechanism can well be advocated for the effectiveness of Nifedipine against pathologies of the anal canal like anal fissure, anal tenesmus and haemorrhoids.

In the present specification its efficacy when used as a gel for treatment of disorders like acute anal fissure, anal tenesmus, and first and second degree haemorrhoids is shown. All of the above diseases can be accounted for by a marked hypertonicity of the sphincter.

Targeting and overcoming sphincter hypertonicity leads to efficacious functional

treatments of several proctologic pathologies and disorders due to organic pathologies like rectal tenesmus during ulcerative cholangitis of the rectum.

Sphincter hypertonicity is often associated  
5 with other contributory causes like mechanical lesions given by hard stools, and skin lacerations in acute enteritis, ulceration in intra-anal thrombosis, cryptitis and overuse of laxatives.

Sphincter hypertonicity of the continual  
10 type, in its internal region, is brought about by an inflammatory infiltrate from an anal skin lesion, whilst, concomitantly, the external sphincter responds with cramp-like contractions.

This sort of cause-to-effect phenomenology  
15 becomes a vicious circle whose severity is proven by its very low tendency to remission.

In the above scenario, Nifedipine has been proven to play a crucial role in inhibiting the flow of  $Ca^{++}$  ions into the sarcoplasm of the smooth muscle  
20 cells which is known to cause a contraction of the muscle fibres.

Hence its local use as a gel yields to a relaxation of the internal anal region of the sphincter.

25 Ancillary, Nifedipine has been advantageously proven by experimental studies to have an antiinflammatory action, a modulating effect on the microcirculation and an ability to act locally.

This further action quenches the inflammation

which is known to confer momentum to the pathologic interactions that establish between the internal and the external regions of the sphincter and can be advocated in the proctologic pathologies which are  
5 sustained by a hyertonicity of the internal and external anal sphincter.

Use of Nifedipine in association with pharmaceuticals such as local anaesthetics, lidocaine, carbocaine and alikes is also viable. Furthermore its  
10 association with non-steroidal or caustic antiinflammatories, mesclepine and with whichever pharmaceutical with therapeutical viability within therapies against ulcerous recto-cholitis and aspecific proctites has been seen to yield to positive results.

15 These and other features will be more readily apparent from the following examples offered to illustrate but not limit the invention.

Clinical trials were conducted on 423 patients suffering from anal fissure, anal tenesmus and  
20 haemorrhoids. These were subdivided into six groups, of which three control groups underwent standard treatments according to traditional conservative protocols, while the other three groups of patients were treated by local application of Nifedipine gel.

25 The patients were subdivided into 3 groups:  
Group 1: 283 individuals suffering from acute anal fissure.  
Group 2: 60 individuals suffering from haemorrhoids.  
Group 3: 80 individuals suffering from anal tenesmus,

48 of whom had an associated ulcerative cholangitis of the rectum.

A selection was made and patients were not admitted to the groups in case of presumed or confirmed pregnancy, chronic anal fissure warranting surgery, third or fourth degree haemorrhoids, allergy to nifedipine.

All groups were similar in terms of age and sex, and they were further subdivided into two subgroups: the control patients who received a standard conservative therapy that consisted of a suitable diet, the use of laxatives and the local application of a gel containing a local anaesthetic and/or anti-inflammatory drugs, in association with an anal dilator; and the Nifedipine patients whose protocol consisted of the local application of 5 mg Nifedipine gel aliquots every 12 hours for a 21 day long period.

Every single patient underwent a standard clinical examination, proctoscopy and anorectal manometry with pressure readings in relaxation and contraction. Furthermore they were asked to answer a questionnaire wherein they could appraise the pain and symptoms they suffered from by categorising them as persistent, modest, or absent.

The above tests were conducted right before the beginning of treatment as well as on its 14th and 21st days.

Example 1. Patients suffering from anal fissure.



Two subgroups with 141 and 142 patients suffering from the above and aged  $47 \pm 10$  years respectively were considered.

Clinical and manometer examinations showed that 80% of the patients were affected by substantial hypertonicity. A total remission from acute anal fissure was recorded in 95% of the patients treated with Nifedipine, whereas the same positive results were observed in only 50% of the control patients; pain was seen to be absent, modest and persistent respectively in 65%, 30% and 5% of the patients in the Nifedipine group, whereas patients in the control group were as many as 40%, 30% and 30%. Moreover, anorectal manometry showed normalisation of the sphincter tone in as many as 80% of the patients in the Nifedipine subgroup, against the mere 35% of the control patients.

The results are summarised in table 1 below.

Table 1

Group	No. of patients	Clinical evaluation of pain (%)			Anorectal Manometry normalization of sphincter tone (%)	Total remission (%)
		absent	modest	persistent		
Nifedipine Subgroup	141	65	30	5	80	95
Control subgroup	142	40	30	30	35	50

Example 2. Patients suffering from haemorrhoids.

Two subgroups made up of 31 and 29 patients aged 45  $\pm$ 10.8 years were monitored. Only patients affected by sphincter hypertonicity were considered, and this was detected by manometer examination. After just 14 days of treatment, patients affected by haemorrhoids that showed a substantial improvement symptomwise and a reduction in the degree were as many as 67% in the Nifedipine group, whereas they reached a mere 27% in the control group. The above percentages soared to 70% and 38% respectively, at the end of the 21 days of treatment. Moreover, anorectal manometry showed a more drastic reduction in hypertonicity in the patients of the Nifedipine group, in comparison with those of the control group, but statistical analysis revealed the difference not to be significant.

The results are shown in table 2 below.

Table 2

Group	No. of patients	Anorectal Manometry: normalization of sphincter tone (%)	Clinical improvement of the symptoms (%)
Nifedipine subgroup	31	61	70
Control subgroup	29	38	38

Example 3. Patients suffering from anal tenesmus.

Two groups made up of 38 and 42 patients aged 38  $\pm$  9.8 years were considered. In as many as 93% of the patients of the Nifedipine group, symptoms disappeared after only a few days, compared with 52% in the control group. Patients suffering from anal tenesmus associated with ulcerative colitis of the rectum were present in equal amounts in both groups, and for these, remission showed to be slower.

The results are summarised in Table 3 below.

Table 3

Group	No. of patients (*)	Anorectal Manometry:		Remission of the symptoms (%)	
		Normalization of sphincter tone(%)		14 days	21 days
		14 days	21 days		
Nifedipine subgroup	38 (23*)	80 (74*)	93 (82*)	93 (82*)	100 (95*)
Control subgroup	42 (25*)	52 (36*)	64 (48*)	52 (44*)	65 (56*)

Considering the positive results of the present clinical experience, it can be seen that the therapeutic use of Nifedipine, which at present concerns cardiovascular pathologies, should be extended with local use, to pathologies like anal fissure, anal tenesmus, and haemorrhoids associated with sphincter hypertonicity. On the basis of other experimental studies conducted by Yousif and Triggle, and published in the Can. J. Physiol Pharmacol 1985, 63, pp.193-195,

the applicant suggests that other pathologies such as ischemic cholangitis, bladder tenesmus and bladder spasm as well as preparation for endoscopic examinations like colonoscopy and cystoscopy could benefit from

5 Nifedipine administered in the form of suppositories or a gel.

## CLAIMS.

1. The use of Nifedipine in making a medicament, which medicament is for local external application in therapies against pathologies comprising anal rhagades, rectal tenesmus, anal spasm, haemorrhoids.

5

2. The use of Nifedipine in making a medicament, according to claim 1, wherein the medicament is in the form of a gel, cream or ointment, also useful in preparation for colonoscopy and cystoscopy.

10

3. The use of Nifedipine in making a medicament, which medicament is for treatment against ischemic cholitis, bladder tenesmus and spasm, in suppository form.

15

4. The use of Nifedipine according to any of the preceding claims in association with pharmaceuticals such as local anaesthetics like lidocaine, carbocaine; non-steroidal or caustic antiinflammatories; mesclepine, and with any pharmaceutical against ulcerous recto-cholitis and aspecific proctites.

20

5. Topical preparation for therapies targeting anal rhagades, rectal tenesmus, anal spasm, haemorrhoids, characterised by the fact that it comprises Nifedipine ranging between 0.5% and 30% by weight, lidocaine

25

hydrochloride ranging between 0.25 and 15% by weight,  
and carriers and eccipients *quantum sufficit*.

6. Topical preparation according to claim 5, wherein  
5 the carriers and eccipients comprise  
polyethyleneglycol, carboxymethylcellulose, glycerine,  
methyl-p-hydroxybenzoate, ethyl-p-hydroxybenzoate,  
propyl-p-hydroxybenzoate, sodium benzoate and water.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IT 98/00040

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/44 //(A61K31/44, 31:165)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 06466 A (KOREN LABORATORIES PTY LTD) 9 March 1995 see the whole document, especially abstract, page 2 lines 7-14, page 4 lines 17-24, page 5 lines 1.-23, page 6 and claims 6,7,9-14,19,20,22-26 ---	1,2,4,5
Y	CHRYEOS ET AL.: "Effect of nifedipine on rectoanal motility" DIS. COLON RECTUM, vol. 39, no. 2, February 1996, pages 212-216, XP002069983 see the whole document --- -/--	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 July 1998

Date of mailing of the international search report

16/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

# INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/IT 98/00040

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	DE 195 39 361 A (BASF AG) 24 April 1997 see the whole document, especially column 2 lines 43-65, columns 3,4, column 5 line 56, coulmn 6 lines 42 and 50, column 7 line 5	5,6
Y	---	1-3
P,Y	MCLOUGHLIN ET AL.: "Using nifedipine to treat tenesmus" PALLIAT. MED., vol. 11, no. 5, September 1997, pages 419-420, XP002069984 see the whole document	1-3
A	---	5,6
A	WO 94 21271 A (CELLEGY PHARMACEUTICALS INC.) 29 September 1994 see page 8 see page 9, line 3 - line 4 see examples 3,10	5,6
A	---	1-3
A	MALMGREN ET AL.: "Effects of nifedipine and Bay K8644 on normal and hypertrophied rat detrusor" NEUROL. URODYN., vol. 7, no. 1, 1988, pages 27-35, XP002069985 see the whole document	1-3
A	---	1-3
A	ANGELICO ET AL.: "In vivo effects of different antispasmodic drugs on the rat bladder contractions induce3d by topically applied KCl" J. PHARMACOL. TOXICOL. LETT., vol. 27, no. 1, March 1992, pages 33-39, XP002069986 see the whole document	1-3
A	---	1-3
A	ZAR ET AL.: "Effect of nifedipine on the contractile responses of the isolated rat bladder" J. UROL. , vol. 143, no. 4, April 1990, pages 835-839, XP002069987 see the whole document	1-3
A	---	1-3
A	PLANTE P.: "La contraction vésicale. II. Analyse biomécanique de la contraction vésicale" J. UROL., vol. 89, no. 7, 1983, pages 461-482, XP002069988 see page 469, right-hand column, paragraph 1 see page 469, left-hand column, paragraph 1	1-3
	-----	



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 98/00040

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9506466 A	09-03-1995	AU 7454594 A ZA 9500511 A	22-03-1995 11-03-1996
DE 19539361 A	24-04-1997	AU 7491296 A WO 9715293 A	15-05-1997 01-05-1997
WO 9421271 A	29-09-1994	AU 6413694 A EP 0693932 A	11-10-1994 31-01-1996

**THIS PAGE BLANK (USPTO)**